AngioDynamics CEO Highlights Debt-Free Turnaround, Auryon Gains, and NanoKnife Launch

Clemmer touts MedTech growth, outlines plans for key platforms at Needham Healthcare Conference

Apr. 15, 2026 at 11:26am

Got story updates? Submit your updates here. ›

A close-up, high-contrast photograph of a sleek, metallic medical device with smooth, geometric shapes, representing the advanced technology and precision of AngioDynamics' innovative product portfolio.AngioDynamics' innovative medical devices, like the Auryon laser atherectomy platform, are driving the company's strategic transformation and growth in the MedTech sector.Latham Today

AngioDynamics CEO Jim Clemmer used a presentation at the Needham & Company's 25th Annual Needham Healthcare Conference to outline the company's multi-year transformation, highlight growth drivers in its MedTech segment, and discuss clinical and commercial plans for its three primary platforms: Auryon, AngioVac/AlphaVac, and NanoKnife.

Why it matters

AngioDynamics has undergone a strategic reset in recent years, divesting less attractive product lines and focusing on innovation and balance sheet strengthening. The company's MedTech segment, now nearly half of total revenue, is positioned as the future growth engine, driven by platforms like Auryon, AngioVac, and NanoKnife.

The details

Clemmer said AngioDynamics has grown its MedTech segment at a 25% compound annual growth rate, with Auryon laser atherectomy now the number-three player in its category. The company also highlighted progress with AngioVac and AlphaVac for venous thromboembolism treatment, as well as the FDA clearance and commercial launch of the NanoKnife system for prostate cancer focal therapy.

  • AngioDynamics launched the Auryon laser atherectomy platform commercially in September 2020.
  • NanoKnife received FDA clearance in December 2024 and obtained a CPT I code effective January 1, 2025.

The players

Jim Clemmer

CEO of AngioDynamics, a medical technology company headquartered in Latham, New York.

AngioDynamics

A medical technology company that develops, manufactures, and markets a broad range of minimally invasive medical devices, with a focus on vascular access, peripheral vascular intervention, and interventional oncology.

Auryon

AngioDynamics' laser atherectomy platform for the treatment of peripheral arterial disease, which the company entered after a 2019 acquisition and launched commercially in 2020.

AngioVac

AngioDynamics' foundational platform for extracting clot or vegetation and reinfusing blood during complex procedures, which the company has had on the market for about 10 years.

AlphaVac

AngioDynamics' purpose-built pulmonary embolism thrombectomy device, developed after physician requests for a steerable, aspiration-controlled system paired with the 'vortex funnel tip' design associated with AngioVac.

NanoKnife

AngioDynamics' system for focal therapy in intermediate-risk prostate cancer, which received FDA clearance in December 2024 and uses electrical pulses to create 'nano-sized particle holes' in tissue, leading tumors to die naturally while limiting disruption to surrounding functions.

Got photos? Submit your photos here. ›

What they’re saying

“It's about 50/50”

— Jim Clemmer, CEO, AngioDynamics

“We've seen some change and disruption, but have remained focused on expanding our own commercial and clinical footprint.”

— Jim Clemmer, CEO, AngioDynamics

What’s next

AngioDynamics is working with the FDA on a study design to potentially move the Auryon laser atherectomy platform into the coronary arterial market, a process that could take a few years.

The takeaway

AngioDynamics' strategic reset and focus on innovation in its MedTech segment, including platforms like Auryon, AngioVac, AlphaVac, and NanoKnife, have positioned the company for growth and margin expansion as it transitions to a 'pure play' medical technology company.